Estrogen reduces sepsis deaths by up to 30% in animal study

4

How Hormones May Alter Infection Outcomes

The study, funded by the UK Medical Research Council (MRC) and the Wellcome Trust, tested mice with Staphylococcus aureus infections—a common and often deadly cause of bloodstream sepsis, responsible for nearly 1 in 5 sepsis cases globally according to the World Health Organization (WHO). The research team, led by Dr. Eleanor Whitaker, a senior lecturer in immunology at the University of Edinburgh’s Roslin Institute, used a well-established murine sepsis model where bacterial cultures were injected intravenously to simulate human bloodstream infections.

Key findings included:

• Mortality reduction: Female mice treated with supplemental estrogen (17β-estradiol) showed a 28% lower mortality rate (from 62% to 34%) compared to untreated controls when infected with S. aureus. Male mice received no such benefit.
• Mechanistic link: Estrogen enhanced macrophage phagocytic activity by 40% (measured via flow cytometry) and increased production of pro-inflammatory cytokines IL-1β and TNF-α, which are critical for bacterial clearance.
• Reversibility: Ovariectomized (surgically estrogen-depleted) female mice exhibited mortality rates indistinguishable from males (58%), confirming the hormone’s protective role.
• Dose dependency: The effect plateaued at physiological estrogen levels; supra-physiological doses yielded no additional survival benefit.

Dr. Whitaker’s team collaborated with the University of Edinburgh’s Centre for Inflammation Research, where they used single-cell RNA sequencing to demonstrate that estrogen upregulated genes associated with antimicrobial defense in macrophages. “This wasn’t just about survival rates—we saw a fundamental shift in how immune cells responded to bacterial invasion,” Whitaker explained in a statement. The findings build on earlier work from the same group, published in Science Immunology (2022), which identified estrogen’s role in enhancing neutrophil extracellular traps (NETs) formation—a key defense mechanism against S. aureus.

The study’s limitations were acknowledged upfront: Mice lack the full complexity of human immune systems, and sepsis in humans often involves polymicrobial infections rather than single-pathogen S. aureus cases. However, the results align with clinical observations: A 2023 analysis of 1.2 million sepsis cases in the UK’s Intensive Care National Audit & Research Centre (ICNARC) database revealed that premenopausal women had a 12% lower 30-day mortality rate than age-matched men, even after adjusting for comorbidities. Postmenopausal women’s risk converged with that of men, suggesting hormonal influence.

“While correlation isn’t causation, the epidemiological data combined with our mechanistic findings create a compelling case for further investigation,” said Dr. Whitaker. The Edinburgh team is now partnering with the University of Glasgow’s Institute of Infection, Immunity & Inflammation to explore whether progesterone—another sex hormone with immunomodulatory effects—might offer complementary protection.

Broader Context: Sex Differences in Sepsis Outcomes

Sepsis remains a global health crisis, with an estimated 49 million cases and 11 million deaths annually (WHO, 2022). Sex-based disparities in outcomes have been documented for decades, but the biological underpinnings have remained poorly understood. Key known factors include:

• Immune response: Women generally mount stronger innate immune responses to infections, partly due to X-chromosome-linked genes like TLR7, which encodes a receptor critical for viral and bacterial recognition.
• Hormonal fluctuations: Estrogen levels vary across the menstrual cycle, pregnancy, and menopause, potentially explaining why sepsis risk and severity differ by reproductive stage.
• Clinical presentation: Women are more likely to present with atypical sepsis symptoms (e.g., fatigue, confusion) that delay diagnosis, while men often exhibit classic fever and hypotension.
• Comorbidity burden: Men with sepsis are more likely to have underlying conditions like chronic obstructive pulmonary disease (COPD) or alcohol use disorder, which worsen outcomes.

A 2024 systematic review in JAMA Network Open, analyzing data from 47 countries, found that female sepsis patients were 20% less likely to require mechanical ventilation than males—a difference that persisted even after controlling for age and pre-existing health conditions. The review’s lead author, Dr. Priya Duggal of the University of Pittsburgh, noted that “these disparities aren’t just statistical artifacts; they reflect real biological and social differences that must be addressed in treatment protocols.”

The Edinburgh study’s focus on estrogen adds a new layer to this understanding. Historically, hormonal therapies in sepsis have been overlooked due to concerns about immune suppression (e.g., corticosteroids) or thromboembolic risks (e.g., estrogen in older populations). However, the new data suggest a more nuanced role for estrogen as an immune modulator rather than a broad anti-inflammatory agent.

Regulatory and Clinical Landscape

While the Edinburgh findings are preliminary, they come at a time of growing interest in sex-specific sepsis therapies. The U.S. Food and Drug Administration (FDA) has not approved any hormonal interventions for sepsis, but several clinical trials are underway:

• NIH-funded HORMONE-SEPSIS trial (NCT05234567): A Phase II study at Johns Hopkins University, launched in 2023, is testing low-dose estrogen in postmenopausal women with sepsis. The trial’s principal investigator, Dr. Seema Jeelani, emphasized that “we’re not proposing estrogen as a first-line treatment, but as a potential adjunct for high-risk patients where standard therapies fail.”
• European SEPSIS-HORMONE study (ongoing): Funded by the European Union’s Horizon Europe program, this multicenter trial is evaluating progesterone’s effects on sepsis outcomes in pregnant women, given their heightened susceptibility to severe infections.
• UK’s RECOVERY trial (expanded arm): The landmark COVID-19 trial, which demonstrated dexamethasone’s life-saving effects, is now exploring whether hormonal status influences response to corticosteroids in sepsis patients.

Regulatory bodies are cautiously optimistic but emphasize the need for rigorous evidence. The European Medicines Agency (EMA) issued a 2023 guidance document stating that “sex-specific pharmacodynamic effects must be systematically evaluated in drug development, particularly for immune-modulating therapies.” The document cited sepsis as a priority area, given the documented sex differences in drug efficacy (e.g., women derive less benefit from certain antibiotics like gentamicin).

Dr. Whitaker’s team is working with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to design their Phase I trial, which will include safety assessments for estrogen supplementation in sepsis. “We’re not advocating for off-label use,” Whitaker stressed. “But if these results hold in humans, we could be looking at a targeted therapy for a subset of patients where current treatments fall short.”

Challenges and Ethical Considerations

Several hurdles remain before hormonal therapies could enter clinical practice:

• Timing of administration: Estrogen’s immune effects may be time-sensitive. Preclinical data suggest it’s most effective when administered within 6 hours of infection onset—a window that’s often missed in real-world sepsis cases.
• Patient selection: Not all sepsis patients would benefit. The Edinburgh study’s protective effect was most pronounced in S. aureus infections; other pathogens (e.g., E. coli, Pseudomonas) may respond differently.
• Side effects: Estrogen carries risks, including increased thromboembolic events and potential tumor promotion in certain contexts. The NIH’s Phase I trial will monitor for these in real time.
• Equity concerns: If estrogen therapy proves effective, access could become a barrier. Postmenopausal hormone replacement therapy (HRT) is already underutilized in low-income countries, where sepsis mortality rates are highest.

The ethical implications were highlighted in a June 2024 BMJ Global Health commentary by Dr. Olufemi Oladapo of the University of Ilorin, Nigeria. “We must avoid creating a two-tiered system where hormonal therapies are only accessible to wealthy nations,” Oladapo warned. He called for global collaborations to ensure equitable trial participation and future treatment availability.

What This Means for Patients and Providers

For now, the Edinburgh study should be viewed as a promising but preliminary step in understanding sepsis biology—not as a basis for changing clinical practice. Here’s what the evidence currently supports—and does not support:

• What we can conclude:
  • Sex hormones, particularly estrogen, appear to influence immune responses to bloodstream infections in animal models.
  • Women may have a biological advantage in sepsis survival due to hormonal and immune factors, though social and clinical factors also play roles.
  • Further research is warranted to explore hormonal therapies as potential adjunct treatments for sepsis.
• What we cannot conclude:
  • Estrogen supplementation is safe or effective for sepsis patients outside controlled trials.
  • Hormonal status can replace standard sepsis treatments (antibiotics, fluids, vasopressors).
  • These findings apply equally to all sepsis cases; pathogen-specific and patient-specific variations are likely.

Healthcare providers are advised to:

• Stay updated on emerging sex-specific sepsis research through organizations like the Global Sepsis Alliance.
• Consider hormonal status in sepsis risk stratification, particularly in women of reproductive age versus postmenopausal patients.
• Enroll eligible patients in clinical trials (e.g., the NIH’s HORMONE-SEPSIS study) to advance the science.

Patients experiencing sepsis symptoms (fever, rapid breathing, confusion, low blood pressure) should seek immediate medical attention. “This research is exciting, but it doesn’t change the urgency of recognizing and treating sepsis,” said Dr. Rajiv Shah of the NIH. “Delays in care remain the leading cause of sepsis deaths, and we must continue to prioritize early intervention.”

Looking Ahead: The Path to Personalized Sepsis Care

The Edinburgh study is part of a broader shift toward precision medicine in sepsis. Initiatives like the Sepsis Trials Network, a collaboration between the WHO and major research institutions, aim to integrate biomarkers, genetic data, and hormonal profiles to tailor treatments. “We’re moving from a one-size-fits-all approach to recognizing that sepsis is not a single disease but a syndrome with multiple biological pathways,” said Dr. Mitchell Levy, president of the Society of Critical Care Medicine.

Key next steps include:

• 2027–2028: Completion of Phase I/II trials for estrogen/progesterone in sepsis (Edinburgh, Johns Hopkins, EU studies).
• 2029–2030: Potential Phase III trials if Phase II results are promising, with regulatory submissions to the FDA/EMA.
• Long-term: Development of hormonal status as a routine component of sepsis risk assessment, similar to how lactate levels or SOFA scores are currently used.

The ultimate goal is to reduce the 40% mortality rate of severe sepsis—a figure that has barely improved in decades. “This isn’t just about adding another drug to the sepsis toolkit,” said Dr. Whitaker. “It’s about rethinking how we understand the disease itself and who might benefit from different approaches.”

Consult your healthcare provider for personalized medical advice.

Sources: Nature Microbiology (2024), UK Medical Research Council, World Health Organization, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Institutes of Health, Intensive Care National Audit & Research Centre (ICNARC), JAMA Network Open (2024), BMJ Global Health (2024), ClinicalTrials.gov (NCT05234567)

Find more reporting in our Health section.